Hainan Huluwa Pharmaceutical Group Co., Ltd.

Ten years ago, pharma advertising media went something like this: TV, traditional media and maybe some Facebook pages. Fast forward to today, and while TV and traditional print and radio are still media campaign components, social media and digital advertising have skyrocketed. Andrea Palmer, CEO of Publicis Health Media (PHM), which debuted 10 years ago as a pharma and healthcare media buying agency, remembers those days well. Pharma companies’ social media revolved around Facebook pages, although with comments disabled and staying far away from user-generated content. That’s a world away from the current pharma social media scene where social influencers across a wide range of platforms engage with and for pharma brands and companies. “Pharma has gone from risk averse … to figuring out ways to get into these channels in a compliant manner because it’s consumer behavior – the way people consume information and the way people learn,” she said in a recent interview with Endpoints News . “In what I would consider a fairly short time frame of only 10 years, we’ve moved from pretty much one end of the spectrum to very much the other end.” The increasing level of sophistication in pharma marketing and media led PHM to launch a formalized content practice to build better branded engagements, Palmer said, with strategies in areas including branded entertainment, video and audio content. Pharma companies’ once “enormous appetite for more traditional models” hasn’t completely disappeared. But it has evolved from almost all linear TV, that is, television viewing at broadcast or cable channel programmed times, to a broad distribution model through connected TV through online and streaming services like Hulu and Netflix. Traditional media buyers who were “A-plus negotiators” in the marketplace, as Palmer said, are being replaced by digital and social media aces. “Our team of video buyers looks so different today. They are digital natives, they’re data driven and they’re fluent in things like programmatic, and now they’re translating those skills into placing video,” she said. The need for data expertise is due in part to a boom there as well — today one-third of the world’s data is health data, PHM notes. What’s coming in the next 10 years is difficult to predict, of course. As Palmer said, “I wouldn’t have guessed 10 years ago we’d be talking about ChatGPT, so geez, can you imagine what are the next 10 years going to look like?” She did point to more immediate trends, though, and one she regards as a major trend is access to healthcare changes. That includes moves such as Amazon and other new players entering into healthcare, clinical trials becoming more decentralized and retailers moving into the clinic space. “That has a lot of potential influence on where the next 10 years takes us from a media influence perspective. Does that change the way pharma marketers talk about their brands? Unlikely, but I do think it’ll change the way that we look to make connections with patients and I’ll be interested to see how and if that changes the go to market strategies,” Palmer said.

NANNING, China, Aug. 30, 2022 /PRNewswire/ -- Recently, the lung CT image-aided diagnosis software developed by Guangxi Yizhun Intelligent Technology Co., Ltd. ("Yizhun") in National Nanning Economic & Technological Development Area ("Area") has been granted the registration certificate of class III medical devices (GXZZ20223210687). Continue Reading Production workshop of Nanning Neptunus Health Industrial Park Nanning's investment promotion departments at all levels aim at creating biomedical industry clusters through high starting point planning and attraction of targeted investments, according to National Nanning Economic & Technological Development Area Management Committee. In the Area, the biomedical industry, involving the fields of production, inspection & testing, sales and distribution, continually expands in industrial scale and gradually improves in industrial chain. The approved "lung CT image-aided diagnosis software" is the first software in Guangxi province and the country's eighth one with the registration certificate of class III AI medical devices and software, and the sixth in Guangxi province and the second in Nanning city to have received the certificate. This is another achievement of the city's continuous optimization of services for moved-in enterprises and solid efforts in building up the biopharmaceutical industry. In terms of precise investments, the Area has compiled a panorama of biopharmaceutical industry chain, positively brought in investments in the industry chain and industry clusters and introduced a batch of key projects such as Hainan Huluwa Pharmaceutical, Guangdong Yili Pharmaceutical, Yida Xiansheng, Sinopharm Group and Guangxi LiuYao Group, forming an industrial development pattern with biopharmaceuticals, traditional Chinese medicine, health care products, medical devices and modern pharmaceutical logistics as main fields. According to information, the Area is the major ground to develop the biopharmaceutical industry in the city, and there are currently 625 biopharmaceutical enterprises in the Area. Image Attachments Links: Link: Caption: Production workshop of Nanning Neptunus Health Industrial Park SOURCE National Nanning Economic & Technological Development Area Management Committee